Publications by authors named "Yakir Rotenberg"

Claim this Profile
A
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Mor Moskovitz, Elizabeth Dudnik, Sivan Shamai, Yakir Rotenberg, Noa Popovich-Hadari

Oncologist· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations.
Luna Kadouri, Ayala Hubert, Yakir Rotenberg, Tamar Hamburger, Michal Sagi

J Med Genet· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis